The Goldman Sachs Group Begins Coverage on Silence Therapeutics (NASDAQ:SLN)

Equities research analysts at The Goldman Sachs Group initiated coverage on shares of Silence Therapeutics (NASDAQ:SLN) in a research note issued to investors on Tuesday,Briefing.com Automated Import reports. The brokerage set a “sell” rating and a $6.00 price target on the stock. The Goldman Sachs Group’s price objective would indicate a potential upside of 21.95% from the company’s current price.

Several other equities analysts also recently commented on SLN. BMO Capital Markets reissued an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, December 2nd. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Chardan Capital reiterated a “buy” rating and issued a $55.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, December 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Wednesday, January 29th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, Silence Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $45.00.

Silence Therapeutics Price Performance

Silence Therapeutics stock opened at $4.92 on Tuesday. The company has a market capitalization of $147.26 million, a price-to-earnings ratio of -3.13 and a beta of 1.05. Silence Therapeutics has a one year low of $4.82 and a one year high of $27.72. The company’s fifty day moving average price is $6.33 and its two-hundred day moving average price is $13.08.

Hedge Funds Weigh In On Silence Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC increased its stake in Silence Therapeutics by 32.8% during the third quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock valued at $19,798,000 after acquiring an additional 268,250 shares during the period. Eventide Asset Management LLC bought a new position in Silence Therapeutics during the third quarter valued at about $11,635,000. Ikarian Capital LLC increased its stake in Silence Therapeutics by 15.9% during the third quarter. Ikarian Capital LLC now owns 587,343 shares of the company’s stock valued at $10,678,000 after acquiring an additional 80,678 shares during the period. Parkman Healthcare Partners LLC boosted its holdings in Silence Therapeutics by 71.8% during the third quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock valued at $9,051,000 after purchasing an additional 208,029 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its holdings in Silence Therapeutics by 219.3% during the third quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock valued at $8,505,000 after purchasing an additional 321,300 shares in the last quarter. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.